Overview

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the safety, tolerability and maximum tolerated dose of Oral AP23573 in combination with Doxorubicin
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Ariad Pharmaceuticals
Treatments:
Doxorubicin
Liposomal doxorubicin
Sirolimus